Very early researchNot Yet RecruitingNCT06081153What this trial is testingMechanistic Clinical Trial of PCSK9 Inhibition for AAAWho this might be right forAbdominal Aortic Aneurysm University of Pennsylvania 44
Testing effectiveness (Phase 2)Study completedNCT03043365What this trial is testingEffect of Fish Oil Enriched In Omega-11 Fatty Acid On Lipoprotein Metabolism In AdultsWho this might be right forLipoprotein MetabolismPCSK9Proteomics National Heart, Lung, and Blood Institute (NHLBI) 37
Post-approval studies (Phase 4)Looking for participantsNCT06909565What this trial is testingInclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular InterventionWho this might be right forPercutaneous Coronary InterventionPeripheral Endovascular Intervention Duke University 6,000
Not applicableStudy completedNCT01109706What this trial is testingRelevance of Plasma PCSK9 Concentration as a Biomarker in Acute Coronary Syndrome.Who this might be right forAcute Coronary Syndrome Nantes University Hospital 175
Large-scale testing (Phase 3)Study completedNCT05004675What this trial is testingTrial to Evaluate Efficacy and Safety of LIB003 and Inclisiran in High-risk CVD PatientsWho this might be right forHypercholesterolemiaAtherosclerotic Ischemic Disease LIB Therapeutics LLC 166
Large-scale testing (Phase 3)Study completedNCT03207945What this trial is testingEffect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection (EPIC-HIV Study)Who this might be right forDyslipidemiasCardiovascular DiseasesHIV Infections University of California, San Francisco 118
Not applicableUnknownNCT06134635What this trial is testingShort-term Effect of PCSK9 Inhibitor in Patients With Acute Ischemic StrokeWho this might be right forAcute Ischemic Stroke Xuanwu Hospital, Beijing 80
Large-scale testing (Phase 3)Study completedNCT02729025What this trial is testingEffects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflammation in Patients With Elevated Lipoprotein(a) (Lp(a))Who this might be right forSubjects With Hyperlipidemia, Dyslipidemia Amgen 129
Very early researchActive Not RecruitingNCT04862260What this trial is testingCholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic AdenocarcinomaWho this might be right forPancreatic Ductal AdenocarcinomaPancreatic CancerPancreas Cancer+1 more CHU de Quebec-Universite Laval 3
Large-scale testing (Phase 3)Study completedNCT01516879What this trial is testingDurable Effect of PCSK9 Antibody CompARed wiTh placEbo StudyWho this might be right forHypercholesterolemia Amgen 905
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07061535What this trial is testingSintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung CancerWho this might be right forExtensive-stage Small Cell Lung Cancer (ES-SCLC)Extensive Stage Lung Small Cell CancerExtensive-Stage Small-Cell Lung Cancer+1 more Second Affiliated Hospital, School of Medicine, Zhejiang University 40
Not applicableStudy completedNCT07409636What this trial is testingAssess the Real-World Effectiveness of Inclisiran and PCSK9 mAbs in Chinese Hypercholesterolemia Adult PatientsWho this might be right forHypercholesterolemiaMixed Dyslipidemia Novartis Pharmaceuticals 11,991
Not applicableStudy completedNCT00847782What this trial is testingAn Experimental Medicine Study to Evaluate Serum Biomarkers of Lipid MetabolismWho this might be right forAtherosclerosis Bristol-Myers Squibb 150
Large-scale testing (Phase 3)Study completedNCT01763827What this trial is testingMonoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2Who this might be right forHyperlipidemia Amgen 615
Testing effectiveness (Phase 2)Study completedNCT01604824What this trial is testingAlirocumab in Participants With Autosomal Dominant Hypercholesterolemia (ADH) and Gain-of-Function Mutations (GOFm) of the Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Gene or Loss-of-Function Mutations (LOFm) of the Apolipoprotein (Apo) B GeneWho this might be right forHypercholesterolemia Regeneron Pharmaceuticals 23
Post-approval studies (Phase 4)Study completedNCT02948777What this trial is testingEffects of PCSK9 Inhibition by Evolocumab on Postprandial Lipid Metabolism in Type 2 DiabetesWho this might be right forType 2 Diabetes Mellitus Marja-Riitta Taskinen 14
Not applicableUnknownNCT05043740What this trial is testingPCSK9 Inhibitor on ACS Patients With Multivessel Disease and Relatively Low LDL-C Level in Chinese PopulationWho this might be right forAcute Coronary Syndrome Second Xiangya Hospital of Central South University 1,360
Large-scale testing (Phase 3)Active Not RecruitingNCT06492291What this trial is testingOpen-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef ExtensionWho this might be right forHypercholesterolemia Merck Sharp & Dohme LLC 3,000
Large-scale testing (Phase 3)Study completedNCT07295418What this trial is testingSAL003 in Participants With Hypercholesterolemia and Mixed DyslipidemiaWho this might be right forHyperlipidemias Shenzhen Salubris Pharmaceuticals Co., Ltd. 618
Large-scale testing (Phase 3)Active Not RecruitingNCT05360446What this trial is testingCoronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular EventsWho this might be right forCoronary Artery Disease Novartis Pharmaceuticals 610